SG10201911442XA - Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid - Google Patents

Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Info

Publication number
SG10201911442XA
SG10201911442XA SG10201911442XA SG10201911442XA SG10201911442XA SG 10201911442X A SG10201911442X A SG 10201911442XA SG 10201911442X A SG10201911442X A SG 10201911442XA SG 10201911442X A SG10201911442X A SG 10201911442XA SG 10201911442X A SG10201911442X A SG 10201911442XA
Authority
SG
Singapore
Prior art keywords
thioxothiazolidin
ylidene
furan
oxo
benzyl
Prior art date
Application number
SG10201911442XA
Inventor
Antonio J Barbosa
Original Assignee
Gb006 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gb006 Inc filed Critical Gb006 Inc
Publication of SG10201911442XA publication Critical patent/SG10201911442XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201911442XA 2015-06-12 2016-06-10 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid SG10201911442XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175066P 2015-06-12 2015-06-12
US201662275655P 2016-01-06 2016-01-06

Publications (1)

Publication Number Publication Date
SG10201911442XA true SG10201911442XA (en) 2020-02-27

Family

ID=57504544

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201911442XA SG10201911442XA (en) 2015-06-12 2016-06-10 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Country Status (13)

Country Link
US (2) US10723726B2 (en)
EP (1) EP3307722B1 (en)
JP (1) JP2018521121A (en)
KR (1) KR102663856B1 (en)
CN (1) CN107848991B (en)
AU (2) AU2016275125A1 (en)
BR (2) BR122023025347A2 (en)
CA (2) CA3221219A1 (en)
ES (1) ES2896674T3 (en)
IL (1) IL256237B (en)
NZ (1) NZ738836A (en)
SG (1) SG10201911442XA (en)
WO (1) WO2016201356A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016275125A1 (en) 2015-06-12 2018-01-25 Gb006, Inc. Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
US20200123146A1 (en) * 2016-12-29 2020-04-23 Gb006, Inc. Heterocyclic integrin agonists
MX2019011649A (en) * 2017-03-30 2019-12-19 Merck Patent Gmbh Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazoli n-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol.
JP7416540B2 (en) * 2018-11-28 2024-01-17 羅欣薬業(上海)有限公司 Salt form, crystal form of estrogen receptor downregulator and method for producing the same
WO2020236667A1 (en) * 2019-05-17 2020-11-26 Gb006, Inc. Methods of treating cancer
WO2021061665A1 (en) * 2019-09-23 2021-04-01 Gb006, Inc. Integrin agonist prodrugs
WO2021096988A1 (en) 2019-11-12 2021-05-20 Gb006, Inc. Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy
WO2024081449A1 (en) * 2022-10-14 2024-04-18 Rush University Medical Center Cd11b agonists for treatment of autoimmune disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof
EP1654380A4 (en) 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
FI20041129A0 (en) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Thioxothiazolidinone compounds for use as drugs
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
ITMI20042475A1 (en) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl USE OF THIAZOLIDINONIC DERIVATIVES AS THERAPEUTIC AGENTS
WO2008005651A2 (en) * 2006-06-08 2008-01-10 Decode Chemistry, Inc. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
WO2008082537A2 (en) 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
CN103159695B (en) * 2011-12-08 2015-08-12 首都师范大学 HIV can be suppressed to copy and to effective thiazole compound of resistance HIV virus strain and its production and use
AU2013248972A1 (en) 2012-04-20 2014-11-13 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
AU2016275125A1 (en) 2015-06-12 2018-01-25 Gb006, Inc. Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Also Published As

Publication number Publication date
KR20180016443A (en) 2018-02-14
EP3307722B1 (en) 2021-08-04
CA3221219A1 (en) 2016-12-15
ES2896674T3 (en) 2022-02-25
US20200317657A1 (en) 2020-10-08
JP2018521121A (en) 2018-08-02
IL256237A (en) 2018-02-28
AU2020270457B2 (en) 2022-10-20
US10723726B2 (en) 2020-07-28
NZ738836A (en) 2024-03-22
EP3307722A4 (en) 2018-12-05
WO2016201356A1 (en) 2016-12-15
AU2016275125A1 (en) 2018-01-25
CA2988584C (en) 2024-01-23
AU2020270457A1 (en) 2020-12-10
US11111239B2 (en) 2021-09-07
BR122023025347A2 (en) 2024-01-16
US20180354938A1 (en) 2018-12-13
KR102663856B1 (en) 2024-05-07
CN107848991A (en) 2018-03-27
CN107848991B (en) 2022-01-14
CA2988584A1 (en) 2016-12-15
IL256237B (en) 2021-12-01
EP3307722A1 (en) 2018-04-18
BR112017026406A2 (en) 2019-04-02

Similar Documents

Publication Publication Date Title
IL256237A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
IL259698B (en) 2-(3-ethanesulfonylpyridine-2-yl)-5-(trifluoromethanesulfonyl)benzoxazole crystal
LT3371190T (en) Heterocyclic compounds as pi3k-gamma inhibitors
HK1247201A1 (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
KR102254062B9 (en) Trisodium Valsartan: Solid Form of Sacubitril
IL257026A (en) Solid state forms of eluxadoline
ITUB20155853A1 (en) COMPOSITION OF INORGANIC BINDER FOR CASTING
HK1246297A1 (en) Crystal of 3,5-disubstituted benzene alkynyl compound
DK3351633T3 (en) Antisense nucleic acid
PL3107392T3 (en) Fungicidal compositions of pyrazolecarboxylic acid alkoxyamides
SG11201507336WA (en) Solid forms of 5-(halomethyl) furfural and methods for preparing thereof
PL3107391T3 (en) Fungicidal compositions of pyrazolecarboxylic acid alkoxyamides
DK3373931T3 (en) Heterocyclic compounds for the treatment of disease
HUE064755T2 (en) Transition metal-catalyzed protodecarboxylation of alpha-halo-acrylic acid derivatives
CL2016000616A1 (en) Heterocyclic compounds of n-acylimino.
FI20150044A (en) Fatty acid composition
DE112016002427A5 (en) HOIST
DK3280920T3 (en) REVERSIBLE CONNECTION OF MACHINE COMPONENTS
EP3250540B8 (en) Preparation of compounds from levulinic acid
DK3380528T3 (en) STABILIZED STARCH
HK1215542A1 (en) Application of vanadium compounds
IL253055B (en) Method for preparation of certain 1,5-disubstituted tetrazoles
DK3389638T3 (en) PHARMACEUTICAL COMPOSITION COMPRISING PIMOBENDAN
ES1142181Y (en) Game of bricks caravista
DK3283066T3 (en) 4-Phenylbutyric acid derivatives